245 related articles for article (PubMed ID: 8737200)
1. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
van de Werf F
Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
[No Abstract] [Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Lincoff AM; Topol EJ
Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
[No Abstract] [Full Text] [Related]
3. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
EPISTENT Investigators
Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
[TBL] [Abstract][Full Text] [Related]
4. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
Gambassi G; Landolfi R; Bernabei R
N Engl J Med; 1997 Oct; 337(17):1243-4. PubMed ID: 9340528
[No Abstract] [Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
Khan SS; Forrester J
N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
[No Abstract] [Full Text] [Related]
8. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
Reginelli JP; Topol EJ
Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
[No Abstract] [Full Text] [Related]
9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
10. Routine use of abciximab in coronary stenting?
Stables RH
Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
[No Abstract] [Full Text] [Related]
11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
12. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
[No Abstract] [Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
Gambhir DS; Mukhopadhyay S
Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
[No Abstract] [Full Text] [Related]
14. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
Roe MT; Moliterno DJ
J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718
[No Abstract] [Full Text] [Related]
15. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
[No Abstract] [Full Text] [Related]
16. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
Cheng JW
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
[TBL] [Abstract][Full Text] [Related]
17. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
Goldschmidt-Clermont PJ
J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
[No Abstract] [Full Text] [Related]
18. [Glycoprotein IIb/IIIa antagonists].
Hennemann A
Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
[No Abstract] [Full Text] [Related]
19. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
[TBL] [Abstract][Full Text] [Related]
20. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
Scheller B; Hennen B; Böhm M; Nickenig G
Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
